We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have lost about 2.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Editas Q1 Earnings Miss Estimates, Revenues Beat
Editas incurred a loss of 86 cents per share in the first quarter of 2021, which was wider than both the Zacks Consensus Estimate of a loss of 76 cents per share and the year-ago quarter’s loss of 69 cents.
Collaboration, and other research and development revenues comprising the company’s top line came in at $6.5 million in the reported quarter, up 14% year over year. The top line also beat the Zacks Consensus Estimate of $6.3 million.
Majority of the revenues in the reported quarter were recognized under the Company’s strategic alliance with Bristol Myers.
Quarter in Detail
In the first quarter, research and development expenses were $41.9 million, up 21.1% from the year-ago figure due to increased expenses related to clinical pipeline development.
General and administrative expenses increased 20.2% to $21.4 million owing to higher employee-related expenses.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
VGM Scores
At this time, Editas has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Editas has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?
It has been about a month since the last earnings report for Editas Medicine (EDIT - Free Report) . Shares have lost about 2.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Editas due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Editas Q1 Earnings Miss Estimates, Revenues Beat
Editas incurred a loss of 86 cents per share in the first quarter of 2021, which was wider than both the Zacks Consensus Estimate of a loss of 76 cents per share and the year-ago quarter’s loss of 69 cents.
Collaboration, and other research and development revenues comprising the company’s top line came in at $6.5 million in the reported quarter, up 14% year over year. The top line also beat the Zacks Consensus Estimate of $6.3 million.
Majority of the revenues in the reported quarter were recognized under the Company’s strategic alliance with Bristol Myers.
Quarter in Detail
In the first quarter, research and development expenses were $41.9 million, up 21.1% from the year-ago figure due to increased expenses related to clinical pipeline development.
General and administrative expenses increased 20.2% to $21.4 million owing to higher employee-related expenses.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review.
VGM Scores
At this time, Editas has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Editas has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.